AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 3 analysts
Fundamentals
Fundamentals institutional score is 84 using growth durability 83.6.
Valuation
Valuation institutional score is 36 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 94 using mean target upside 35.8%; dispersion penalty 4.7; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 48 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is skewing constructive on impact and recency. Based on 10 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and analyst consensus provide support, while valuation and technical structure remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 15.6% above historical median. Valuation is rising — currently in the overvalued zone (z-score: +0.49). Confidence: 70%.
Live forward EPS implies next-12-month EPS of ₹95.40. Applying the stock's normalized valuation corridor produces a fair range of ₹968.31 to ₹1,385.21, with base value near ₹1,231.61 (+23.9% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹95.40
Forward P/E
10.4x
Base Fair Value
₹1,231.61
Fair Range
₹968.31 - ₹1,385.21
Upside To Base
+23.9%
Estimate Source
Live forward EPS
Growth Estimate
+57.4%
5Y Average
10.25
Current
14.92
Overvalued
14.52
Undervalued
10.15
5Y Average
9.01
Current
13.12
Overvalued
11.71
Undervalued
4.64
5Y Average
1.26
Current
1.83
Overvalued
1.45
Undervalued
1.07
Peers & Comparison
Sector: Health Care · Theme: Pharmaceuticals
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
ALIVUS LIFE SCIENCES LTD ALIVUSPharmaceuticals | +6.4% | 23.3% | 28.1x Undervalued | -46% vs avg | +44.2% |
JEENA SIKHO LIFECARE LTD JSLLPharmaceuticals | +28.8% | 27.8% | 29.4x Undervalued | -44% vs avg | -22.5% |
COHANCE LIFESCIENCES LTD COHANCEPharmaceuticals | -23.1% | 5.0% | 169.5x Premium | +224% vs avg | -51.4% |
AKUMS DRUGS AND PHARMA L AKUMSPharmaceuticals | +9.6% | 5.9% | 39.5x Undervalued | -24% vs avg | +59.3% |
BLUE JET HEALTHCARE LTD BLUEJETPharmaceuticals | -17.4% | 26.5% | 43.9x Undervalued | -16% vs avg | -25.1% |
CAPLIN POINT LAB LTD. CAPLIPOINTPharmaceuticals | +19.0% | 29.3% | 28.6x Undervalued | -45% vs avg | +15.8% |
IPCA LABORATORIES LTD IPCALABPharmaceuticals | +6.3% | 11.8% | 39.9x Undervalued | -24% vs avg | +29.3% |
AJANTA PHARMA LIMITED AJANTPHARMPharmaceuticals | +24.8% | 19.6% | 39.9x Undervalued | -24% vs avg | +31.8% |
STRIDES PHARMA SCI LTD trades at a discount (14.9x vs peer avg 52.3x), suggesting potential undervaluation relative to the Pharmaceuticals cohort. Peers include ALIVUS LIFE SCIENCES LTD, JEENA SIKHO LIFECARE LTD, COHANCE LIFESCIENCES LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹554 CrDec 2025Latest net profit
₹122 CrDec 2025Latest EPS
₹13.22Dec 2025Net margin
10.6%Dec 2025Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Dec 2025
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 564 | 475 | 553 | 380 | 603 | 513 | 520 | 551 | 556 | 499 | 522 | 554 |
| Expenses | 444 | 420 | 514 | 378 | 492 | 448 | 464 | 477 | 488 | 431 | 460 | 472 |
| Operating Profit | 96.72 | 34.11 | 15.41 | -20.05 | 89.48 | 44.42 | 34.68 | 53.18 | 45.56 | 45.09 | 40.71 | 58.82 |
| OPM % | 17.16% | 7.18% | 2.79% | -5.28% | 14.84% | 8.66% | 6.68% | 9.65% | 8.19% | 9.04% | 7.8% | 10.62% |
| Other Income | 26.38 | 11.65 | 19.46 | 4.9 | 25.65 | 8.09 | 23.55 | 2.43 | 12.12 | 1.76 | 14.09 | 103 |
| Interest | 42.9 | 36.63 | 41.72 | 36.24 | 39.05 | 40.51 | 41.83 | 34.21 | 29.36 | 30.45 | 29.41 | 27.25 |
| Depreciation | 22.71 | 21.46 | 23.03 | 21.52 | 21.92 | 20.62 | 20.7 | 20.92 | 22.37 | 22.14 | 21.51 | 22.4 |
| Profit before tax | 80.2 | 9.13 | -6.85 | -51.39 | 76.08 | 12 | 16.4 | 21.4 | 28.32 | 16.4 | 25.39 | 135 |
| Tax % | 32.18% | 15.99% | 1.46% | -7.01% | -0.17% | 9.75% | 13.11% | 30.09% | 61.55% | 18.9% | 18.59% | 9.58% |
| Net Profit | 54.39 | 7.67 | -6.75 | -54.99 | 76.21 | 10.83 | 14.25 | 14.96 | 10.89 | 13.3 | 20.67 | 122 |
| EPS in Rs | 6.91 | 0.89 | -0.75 | -0.04 | 5.84 | 308.77 | 1.88 | 1.62 | 1.75 | 1.45 | 3.48 | 13.22 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.